Dr. Kim on Evolution of Treatment Outcomes in Melanoma

Video

Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses how treatment outcomes in melanoma have evolved over the last few years.

Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses how treatment outcomes in melanoma have evolved over the last few years.

For patients with metastatic melanoma in the past, Kim says that trial results with chemotherapy showed an overall survival (OS) rate of 6-9 months, with a maximum of 12 months. Today, OS for a patient receiving targeted therapy or immunotherapy is at least 2 years.

Kim believes there are currently more patients with metastatic melanoma alive at the 3- and 5-year mark of diagnosis because of these advances.

Future studies will show more data regarding long-term control for patients with melanoma.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,